ADIPOQ and neoplasm: Concurrently, altered adipokine signaling—characterized by elevated leptin and reduced adiponectin levels—exacerbates this process by enhancing pro-inflammatory and pro-fibrotic pathways, which may also contribute to a more aggressive tumor microenvironment and poorer oncologic outcomes.